Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 18
- Registration Number
- NCT00448227
- Locations
- 🇺🇸
Children's Memorial Hospital Chicago, Chicago, Illinois, United States
🇺🇸Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸Archana Chatterjee, Omaha, Nebraska, United States
Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00447694
- Locations
- 🇺🇸
Children's Hospital and Research Center at Oakland, Oakland, California, United States
🇺🇸Childrens Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Children's Memorial Hospital, Chicago, Illinois, United States
Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 403
- Registration Number
- NCT00446524
- Locations
- 🇯🇵
Novartis Investigative Site, Fukuoka, Japan
Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy
- Conditions
- Hypertension; Hypertrophy, Left Ventricular
- Interventions
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 90
- Registration Number
- NCT00446563
- Locations
- 🇩🇪
25 centers in Germany, Ludwigshafen, Germany
Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function
- Conditions
- MalariaFalciparum
- Interventions
- First Posted Date
- 2007-03-07
- Last Posted Date
- 2011-04-05
- Lead Sponsor
- Novartis
- Target Recruit Count
- 265
- Registration Number
- NCT00444106
- Locations
- 🇨🇴
Novartis Investigational Site, Tumaco, Colombia
Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)
- Conditions
- Asthma
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 50
- Registration Number
- NCT00443482
- Locations
- 🇩🇪
Novartis Investigative Site, Wiesbaden, Germany
Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren
- First Posted Date
- 2007-02-28
- Last Posted Date
- 2011-03-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 132
- Registration Number
- NCT00441064
- Locations
- 🇺🇸
Novartis US, Madison, Wisconsin, United States
Efficacy and Safety of Diclofenac Sodium (0.1%) Gel in Patients With UV Induced Painful Sunburn
- Conditions
- Sunburn
- First Posted Date
- 2007-02-28
- Last Posted Date
- 2007-02-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 45
- Registration Number
- NCT00441051
- Locations
- 🇫🇷
CPCAD, Nice, France
Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2011-04-20
- Lead Sponsor
- Novartis
- Target Recruit Count
- 412
- Registration Number
- NCT00439244
- Locations
- 🇩🇪
Novartis Investigative site, Wuerzburg, Germany
🇪🇸Novartis Investigative Site, Valencia, Spain
Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
- Conditions
- Macular DegenerationChoroidal Neovascularization
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 321
- Registration Number
- NCT00436553
- Locations
- 🇺🇸
Novartis Investigative SIte, Royal Oak, Michigan, United States
🇨🇦Ivey Eye Institute, Dr. Thomas Sheidow, London, Ontario, Canada
🇺🇸West Coast Retina Medical Group Inc. - 185 Berry St. Suite 130, San Francisco, California, United States